When is the use of intravenous immunoglobulin appropriate in immune thrombocytopaenia?

• Published in: British journal of haematology
• Main Authors: Dubois, Sydney, Layese, Richard, Limal, Nicolas, Languille, Laetitia, Kini-Matondo, Willy, Mahevas, Matthieu, Michel, Marc, Audureau, Etienne, Godeau, Bertrand
• Format: Journal Article
• Language: English
• Published: England 10-10-2024
• Subjects: intravenous immunoglobulin; immune thrombocytopaenia
• DOI: 10.1111/bjh.19817
• EISSN: 1365-2141

Intravenous immunoglobulin (IVIg) is the gold standard treatment for severe cases of immune thrombocytopaenia (ITP). However, its cost, limited duration of efficacy and market supply tension have led French guidelines to reserve IVIg for ITP patients with formal contra-indications to corticosteroids, with French bleeding score ('Khellaf score') > 8, and corticosteroid-resistant patients either with Khellaf score ≤ 8 or in preparation for an invasive procedure or during pregnancy. We studied the prescribing practices of IVIg for ITP in real-life conditions and assessed their compliance with French guidelines. A monocentric retrospective study was conducted between 2016 and 2020 among 114 patients hospitalized in our unit, for a total of 208 IVIg treatments. In 37% of cases, the Khellaf score was >8, validating IVIg prescription according to French guidelines. In the remaining cases, reasons noted for use of IVIg included corticosteroid resistance (33.7%), preparation for an invasive procedure (8.5%), context of pregnancy (6.6%) and contra-indication to corticosteroids (3.3%). After analysis, IVIg prescription was considered valid according to current French guidelines in 84.4% of cases. Non-compliant IVIg prescription was more frequent in younger patients (p = 0.027). Concomitant anti-coagulation was also noted as an argument for IVIg prescription outside of the current French guidelines.